Streetbeat News

Price Targets

CLX

Evercore ISI Group analyst Javier Escalante maintains an 'Underperform' rating on Clorox (NYSE:CLX) and has lowered the price target from $160 to $120.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:45 pm

ALPN

RBC Capital Markets has initiated coverage on Alpine Immune Sciences Inc (NASDAQ:ALPN) with an Outperform rating and a price target of $19. The analysts perceive ALPN's lead candidate, povetacicept, as having a robust foundation for advancement in autoimmune indications. The IgAN treatment market, the primary focus of the RUBY-3 trial, is estimated to be worth over $6 billion by 2032. ALPN shares are up 5.73% at $12.37.

Portfolio Pulse from Vandana Singh

October 05, 2023 | 6:45 pm

CMBM

Roth MKM analyst Scott Searle maintains a 'Buy' rating on Cambium Networks (NASDAQ:CMBM) but has lowered the price target from $25 to $12.5.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:36 pm

HELE

DA Davidson analyst Linda Bolton Weiser maintains a 'Buy' rating on Helen Of Troy (NASDAQ:HELE) but lowers the price target from $159 to $142.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:33 pm

ACCD

Canaccord Genuity analyst Richard Close has maintained a 'Buy' rating on Accolade (NASDAQ:ACCD) but lowered the price target from $18 to $17.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:32 pm

ANGO

Canaccord Genuity analyst William Plovanic maintains a 'Buy' rating on AngioDynamics (NASDAQ:ANGO) but lowers the price target from $20 to $17.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:30 pm

HELE

Canaccord Genuity analyst Susan Anderson has maintained a 'Buy' rating on Helen Of Troy (NASDAQ:HELE) but lowered the price target from $155 to $143.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:24 pm

PEAK

Scotiabank analyst Nicholas Yulico has maintained a 'Sector Perform' rating on Healthpeak Properties (NYSE:PEAK) but lowered the price target from $22 to $20.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:22 pm

BB

TD Securities analyst Daniel Chan has maintained a 'Hold' rating on BlackBerry (NYSE:BB) and lowered the price target from $5 to $4.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:19 pm

CLS

TD Securities analyst Daniel Chan maintains a Buy rating on Celestica (NYSE:CLS) and raises the price target from $23 to $29.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 6:17 pm